Stock Evaluator: Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Inc. GALT

$2.69 -0.12 -4.27%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 257,651
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Commentary & Analysis


Financial Summary

Share Statistics GALT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $271.4 $203.5 32%
Shares Out (Mil) 89.6 55.2 59%
Institutional Ownership 25.7% 93.3% 11%
Float (Mil) 47.9 40.4 45%
Beta 0.50 1.05 27%
Avg Daily Volume (000s) 210 569 45%
Price Change
(52-week)
(53.1%) 38.8% 20%
Growth GALT Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (5.6%) (10.7%) 33%
EPS (5yr) (3.2%) 15.4% 27
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 16.1% (15.7%) 75%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials GALT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($23) ($44) 22%
EPS (TTM) ($0.327) ($1.400) 30%
Operating Cash Flow (TTM) (Mil) ($15) ($35) 17%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) $334 $142 31%
Valuation GALT Industry
Median
Percentile
(All Stocks)
P/B na 1.96 na
P/E na 16.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios GALT Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (179.3%) (47.0%) 2%
ROE 28.7% (51.8%) 86%
Liabilities to Assets 357.0% 29.6% 100%
F-Score 2 3 7%

Galectin Therapeutics Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors